AT-56

• Description:

  AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H228, H315, H319

• Target:

  PGE synthase

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/at-56.html

• Purity:

  99.75

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  N1(CCCCC2=NNN=N2)CC/C(CC1)=C3C4=CC=CC=C4C=CC5=CC=CC=C/35

• Molecular Formula:

  C25H27N5

• Molecular Weight:

  397.52

• Precautions:

  H228, H315, H319

• References & Citations:

  [1]Irikura D, et, al. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. J Biol Chem. 2009 Mar 20; 284 (12) : 7623-30.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  162640-98-4